Abbott To Acquire Exact Sciences For Up To $23B

Under the deal, Exact Sciences shareholders will receive $105 per common share in cash.
In this photo illustration, Exact Sciences logo of a molecular diagnostics company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
In this photo illustration, Exact Sciences logo of a molecular diagnostics company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Nov 20, 2025   |   8:03 AM EST
Share
·
Add us onAdd us on Google

Abbott (ABT) on Thursday said that it has entered into a definitive agreement to acquire Exact Sciences (EXAS) for up to $23 billion.

Under the deal, Exact Sciences shareholders will receive $105 per common share in cash. The transaction is expected to close in the second quarter of 2026, subject to the receipt of necessary approvals.

The transaction was unanimously approved by both companies' boards of directors, the companies said. 

Get updates to this developing story directly on Stocktwits.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy